Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947707 | 0.76 | CHRNA7 (0.45) | CHRNA7KCNH2 | |
| SCHEMBL2943783 | 0.74 | CHRNA7 (0.47) | CHRNA7KCNH2 | |
| SCHEMBL2949253 | 0.71 | CHRNA7 (0.50) | CHRNA7KCNH2 | |
| Benzene SCHEMBL2929682 | 0.66 | CHRNA7 (0.44) | CHRNA7KCNH2 | |
| SCHEMBL4839260 | 0.64 | CHRNA7 (0.47) | CHRNA7KCNH2 | |
| SCHEMBL4109514 | 0.61 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL6627648 | 0.61 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL4109510 | 0.61 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL4109513 | 0.61 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL9141111 | 0.60 | CHRNA7 (0.44) | CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750011-B2 | Diazabicyclic aryl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2010-07-06 | — | — | US | claimed |
| US-20080161314-A1 | Novel Diazabicyclic Aryl Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-07-03 | — | — | US | claimed |
| EP-1866314-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-19 | — | — | EP | claimed |
| WO-2006087305-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-08-24 | — | — | WO | claimed |
| US-7750011-B2 | Diazabicyclic aryl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2010-07-06 | — | — | US | disclosed |
| US-20080161314-A1 | Novel Diazabicyclic Aryl Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-07-03 | — | — | US | disclosed |
| EP-1866314-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006087305-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161314-A1 | Novel Diazabicyclic Aryl Derivatives and Their Medical Use | CHRNA6, CHRNA10, CHRNA2 | CHRNA7 7/4885KCNH2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.